Ischemic stroke is among the most severe diseases threatening human health, of which atherosclerosis is the main pathophysiological basis. In recent years, both basic and clinical studies have confirmed that the immune system plays a core regulatory role in the occurrence and development of atherosclerosis. Some patients with systemic immune diseases are more likely to develop atherosclerosis, and its severity is higher than in patients without systemic immune disorders. Immune cells are also involved in brain tissue damage and repair after ischemic stroke. The clinical application of monoclonal antibodies targeting B cell surface molecules (such as CD20) and survival factors (such as BAFF) in some chronic inflammatory diseases such as rheumatoid arthritis and psoriasis also provides new directions for the immunotherapy in ischemic stroke. However, finding the best target for drug intervention remains the biggest challenge and an attractive target for new strategies for ischemic stroke.
A better understanding of the change rules of immune cells and molecules, the roles of immune response and the mechanisms of how immune cells and mediators are involved in the development of atherosclerosis and stroke-induced neuroinflammation, and the effects of systemic immunological diseases and immunomodulatory drugs on atherosclerosis and ischemic stroke will provide an important basis for an individualized and precise prevention and treatment of ischemic stroke.
This Research Topic will provide a comprehensive overview of the immune system change rules, molecular mechanisms underlying the immune response involved in ischemic stroke, and roles of novel immunomodulators in the development of atherosclerosis and recovery after ischemic stroke. This collection of articles will focus on immune cells and mediators involved in atherosclerosis and ischemic stroke, such as neutrophils, monocytes or macrophages, lymphocyte subsets, macroglia, cytokines, and other immune or inflammatory events and signaling pathways. We welcome the submission of Original Research articles, Reviews covering, but not limited to, the following topics:
- Change rules of immune cells and molecules in the development of atherosclerosis or ischemic stroke
- The relationship among immune cells or molecules and atherosclerosis or ischemic stroke
- Effects of immunomodulatory drugs on atherosclerosis and ischemic stroke
- Cohort study of systemic immune diseases associated with vascular disease
Ischemic stroke is among the most severe diseases threatening human health, of which atherosclerosis is the main pathophysiological basis. In recent years, both basic and clinical studies have confirmed that the immune system plays a core regulatory role in the occurrence and development of atherosclerosis. Some patients with systemic immune diseases are more likely to develop atherosclerosis, and its severity is higher than in patients without systemic immune disorders. Immune cells are also involved in brain tissue damage and repair after ischemic stroke. The clinical application of monoclonal antibodies targeting B cell surface molecules (such as CD20) and survival factors (such as BAFF) in some chronic inflammatory diseases such as rheumatoid arthritis and psoriasis also provides new directions for the immunotherapy in ischemic stroke. However, finding the best target for drug intervention remains the biggest challenge and an attractive target for new strategies for ischemic stroke.
A better understanding of the change rules of immune cells and molecules, the roles of immune response and the mechanisms of how immune cells and mediators are involved in the development of atherosclerosis and stroke-induced neuroinflammation, and the effects of systemic immunological diseases and immunomodulatory drugs on atherosclerosis and ischemic stroke will provide an important basis for an individualized and precise prevention and treatment of ischemic stroke.
This Research Topic will provide a comprehensive overview of the immune system change rules, molecular mechanisms underlying the immune response involved in ischemic stroke, and roles of novel immunomodulators in the development of atherosclerosis and recovery after ischemic stroke. This collection of articles will focus on immune cells and mediators involved in atherosclerosis and ischemic stroke, such as neutrophils, monocytes or macrophages, lymphocyte subsets, macroglia, cytokines, and other immune or inflammatory events and signaling pathways. We welcome the submission of Original Research articles, Reviews covering, but not limited to, the following topics:
- Change rules of immune cells and molecules in the development of atherosclerosis or ischemic stroke
- The relationship among immune cells or molecules and atherosclerosis or ischemic stroke
- Effects of immunomodulatory drugs on atherosclerosis and ischemic stroke
- Cohort study of systemic immune diseases associated with vascular disease
